Sushil K. Badrising
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Brief Report: Reducing Lorlatinib-Related Adverse Events by Establishing the Optimal Exposure-Toxicity Threshold in Patients With NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 10, 2026
Brief report: Reducing Lorlatinib-related Adverse Events by establishing the Optimal Exposure-Toxicity Threshold in Patients with NSCLC.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: March 10, 2026
Determining the optimal approach to identify osimertinib resistance; the first line osimertinib cohort of the OSIRIS study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: June 24, 2025
Tremelimumab plus Durvalumab prior to Chemoradiotherapy in Unresectable, Locally Advanced Non-Small Cell Lung Cancer: The Induction Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 22, 2024
Intracranial Response to Selpercatinib After Pralsetinib-Induced Disease Progression in Rearranged During Transfection Fusion-Positive Non-Small-Cell Lung Cancer: Case Report.
Journal: JTO clinical and research reports
Published: June 17, 2024
Osimertinib with Chemotherapy in EGFR-Mutated NSCLC.
Journal: The New England journal of medicine
Published: January 31, 2024
Prognostic Value of Nivolumab Clearance in Non-Small Cell Lung Cancer Patients for Survival Early in Treatment.
Journal: Clinical pharmacokinetics
Published: September 29, 2023
Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI's: Exploration of efficacy of unselected treatment in a multicenter cohort study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 15, 2023
Integrated analysis of pain, health-related quality of life, and analgesic use in patients with metastatic castration-resistant prostate cancer treated with Radium-223.
Journal: Prostate cancer and prostatic diseases
Published: February 21, 2021
A prospective observational registry evaluating clinical outcomes of Radium-223 treatment in a nonstudy population.
Journal: International journal of cancer
Published: September 21, 2019
Last Updated: 09/26/2026